Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Trident Texofab
Join Channel
Consolidated Standalone

Trident Texofab

₹46.5 -1.5 | 3.2%

Market Cap ₹47 Cr.

Stock P/E 37.8

P/B 2.9

Current Price ₹46.5

Book Value ₹ 16.2

Face Value 10

52W High ₹76.1

Dividend Yield 0%

52W Low ₹ 40.7

Edit Ratio

Trident Texofab Research see more...

Overview Inc. Year: 2008Industry: Textile

Trident Texofab Ltd is an India-based business enterprise engaged in production and presenting of a selection of garments and textile fabric. The Company's product presenting consists of suiting and shirting fabrics, textile fabrics, formal fabric and casual fabric. Textile fabric consist of pareos fabrics, technical textile fabrics, bed sheet fabric, embroidered fabric, headband fabrics, girls dress cloth, dobby fabrics, jacquard fabric and home furnishing fabric. Formal fabrics include female formal fabric and male formal fabric. Casual fabrics consist of girl informal fabrics and male casual fabric.

Read More..

Trident Texofab Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Trident Texofab Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 21 24 25 23 24 25 24 23 23 23
Other Income 0 0 0 0 0 1 1 0 1 0
Total Income 21 24 25 24 24 25 25 23 24 23
Total Expenditure 20 22 24 22 22 22 24 22 22 21
Operating Profit 2 2 1 2 2 3 1 2 2 2
Interest 1 1 0 1 1 1 1 1 1 1
Depreciation 0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses -0 -0 0 0 0 -0 -0 -0 0 0
Profit Before Tax 0 1 0 0 1 2 -0 -0 1 1
Provision for Tax 0 0 -0 0 0 0 -0 -0 0 0
Profit After Tax 0 0 1 0 1 1 0 -0 1 1
Adjustments 0 -0 0 -0 0 0 -0 0 0 0
Profit After Adjustments 0 0 1 0 1 1 0 -0 1 1
Adjusted Earnings Per Share 0 0.1 0.7 0.2 0.8 1.1 0.1 -0.1 0.7 0.6

Trident Texofab Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 34 60 63 66 76 85 87 91 50 84 96 93
Other Income 0 0 0 0 0 0 0 0 2 1 2 2
Total Income 34 61 63 66 76 86 87 91 52 85 98 95
Total Expenditure 33 59 61 65 75 84 84 86 47 80 90 89
Operating Profit 1 1 1 1 1 2 3 5 5 6 8 7
Interest 1 1 1 1 1 1 1 3 3 3 4 4
Depreciation 0 0 0 0 0 0 0 1 1 1 2 0
Exceptional Income / Expenses 0 -0 -0 -0 -0 0 0 -0 0 0 -0 0
Profit Before Tax 0 0 0 0 1 1 2 2 1 1 3 2
Provision for Tax 0 0 0 0 0 0 0 1 1 0 1 0
Profit After Tax 0 0 0 0 0 1 1 1 0 1 2 2
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 0 0 0 0 0 1 1 1 0 1 2 2
Adjusted Earnings Per Share 0 0 0 0 0 0.8 1.3 0.9 0.4 1 2.2 1.3

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 14% 2% 2% 11%
Operating Profit CAGR 33% 17% 32% 23%
PAT CAGR 100% 26% 15% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -28% 15% 3% NA%
ROE Average 16% 9% 10% 8%
ROCE Average 13% 11% 12% 13%

Trident Texofab Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 2 2 3 3 4 8 11 12 12 13 15
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 2 3 1 1 5 4 9 11 19 20 19
Other Non-Current Liabilities 0 0 0 0 0 0 0 4 6 8 6
Total Current Liabilities 15 21 24 34 15 32 27 29 30 30 37
Total Liabilities 19 27 28 38 24 45 47 56 68 71 77
Fixed Assets 2 3 2 1 1 2 2 12 14 22 23
Other Non-Current Assets 0 0 0 0 1 3 8 3 14 9 7
Total Current Assets 17 24 27 36 22 40 36 40 40 40 47
Total Assets 19 27 28 38 24 45 47 56 68 71 77

Trident Texofab Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 0 0 0 0 0 2 0 0 0 0 0
Cash Flow from Operating Activities 1 -1 -0 1 0 -2 -3 -3 2 1 6
Cash Flow from Investing Activities -2 -0 1 -0 -1 -2 -7 -2 -10 -4 0
Cash Flow from Financing Activities 2 1 -1 -1 2 3 10 5 8 3 -6
Net Cash Inflow / Outflow 0 -0 0 -0 2 -2 0 -0 -0 0 0
Closing Cash & Cash Equivalent 0 0 0 0 2 0 0 0 0 0 0

Trident Texofab Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 0 0 0 0 0 0.78 1.33 0.94 0.35 0.98 2.2
CEPS(Rs) 0.42 0.69 0.58 0.3 0.72 0.91 1.65 1.99 1.37 2.43 3.84
DPS(Rs) 0 0 0 0 0 1 1 0 0 0 0
Book NAV/Share(Rs) 0 0 0 0 0 8.62 10.98 11.77 11.85 12.84 15.05
Core EBITDA Margin(%) 2.95 2.03 1.88 1.49 1.51 1.64 2.6 5.01 5.73 5.65 6.49
EBIT Margin(%) 2.73 1.93 1.68 1.06 1.64 2.04 2.77 4.4 7.47 4.85 6.63
Pre Tax Margin(%) 0.72 0.47 0.4 0.14 0.74 1.17 1.83 1.59 1.8 1.5 2.81
PAT Margin (%) 0.35 0.37 0.29 0.09 0.43 0.85 1.38 0.94 0.7 1.16 2.28
Cash Profit Margin (%) 0.58 0.55 0.59 0.29 0.6 0.99 1.71 1.98 2.74 2.89 3.98
ROA(%) 0.63 0.97 0.65 0.18 1.05 2.16 2.77 1.75 0.57 1.42 2.99
ROE(%) 5.64 9.75 6.17 1.7 9.07 12.44 13.56 8.25 3.04 7.91 15.8
ROCE(%) 12.36 13.23 11.91 9.87 15.9 16.1 13.12 14.28 9.8 8.95 13.07
Receivable days 117.64 85.7 105.54 124.28 99.55 97.85 121.88 105.82 205.74 131.83 121.62
Inventory Days 43.17 27.28 33.76 44.25 28.09 15.18 17.81 26.6 65.74 32.95 33.65
Payable days 128.69 87.74 113.83 149.26 115.07 100.52 114.06 82.04 139.92 69.72 65.86
PER(x) 0 0 0 0 0 67.1 30.76 45.98 73.45 63.43 26.12
Price/Book(x) 0 0 0 0 0 6.09 3.72 3.67 2.17 4.82 3.82
Dividend Yield(%) 0 0 0 0 0 0.79 1.02 0 0 0 0
EV/Net Sales(x) 0.16 0.13 0.07 0.05 0.05 0.65 0.62 0.7 1.14 1.16 0.96
EV/Core EBITDA(x) 5.42 6.06 3.38 3.1 2.75 28.53 19.83 12.15 12.03 17.74 11.27
Net Sales Growth(%) 0 75.3 3.47 5.47 15.11 12.53 1.68 4.68 -45.13 68.88 14.32
EBIT Growth(%) 0 24.13 -10.01 -33.72 78.57 44.98 41.41 65.98 -11.36 9.18 56.89
PAT Growth(%) 0 82.98 -19.01 -67.43 460.7 127.87 69.89 -29.34 -60.78 178.31 125.75
EPS Growth(%) 0 0 0 0 0 51.36 69.89 -29.34 -62.65 178.35 125.74
Debt/Equity(x) 2.54 3.18 1.22 0.88 1.41 0.61 1.39 1.94 2.6 2.77 2.29
Current Ratio(x) 1.11 1.11 1.12 1.06 1.43 1.24 1.35 1.37 1.32 1.32 1.25
Quick Ratio(x) 0.84 0.88 0.84 0.79 1.29 1.08 1.2 1.02 1.06 1.08 0.97
Interest Cover(x) 1.36 1.32 1.31 1.15 1.83 2.35 2.95 1.56 1.32 1.45 1.73
Total Debt/Mcap(x) 0 0 0 0 0 0.1 0.38 0.54 1.2 0.57 0.6

Trident Texofab Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 67.04 66.69 64.9 61.09 61.09 61.23 61.23 61.33 61.33 61.74
FII 0 0 0 0 0 0 0 0 0 0
DII 0 0 0 0 0 0 0 0 0 0
Public 32.96 33.31 35.1 38.91 38.91 38.77 38.77 38.67 38.67 38.26
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Debtor days have improved from 69.72 to 65.86days.
  • Company has reduced debt.

Cons

  • Company has a low return on equity of 9% over the last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Trident Texofab News

Top Unlisted Companies & InstaBuy Companies

Sell or Purchase Share (Tentative Price)

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!